Skip Navigation

This Article
Right arrow Full Text Freely available
Right arrow Print PDF (106K) Freely available
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in ISI Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrow Search for citing articles in:
ISI Web of Science (76)
Right arrow Commercial Re-use Guidelines
for Open Access NAR Content
Google Scholar
Right arrow Articles by Bijsterbosch, M. K.
Right arrow Articles by van Berkel, T. J.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Bijsterbosch, M. K.
Right arrow Articles by van Berkel, T. J.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

Nucleic Acids Research, Vol 25, Issue 16 3290-3296, Copyright © 1997 by Oxford University Press

ARTICLES

In vivo fate of phosphorothioate antisense oligodeoxynucleotides: predominant uptake by scavenger receptors on endothelial liver cells

MK Bijsterbosch, M Manoharan, ET Rump, RL De Vrueh, R van Veghel, KL Tivel, EA Biessen, CF Bennett, PD Cook and TJ van Berkel
Division of Biopharmaceutics, Leiden/Amsterdam Center for Drug Research, PO Box 9503, 2300 RA Leiden, The Netherlands.

Systemically administered phosphorothioate antisense oligodeoxynucleotides can specifically affect the expression of their target genes, which affords an exciting new strategy for therapeutic intervention. Earlier studies point to a major role of the liver in the disposition of these oligonucleotides. The aim of the present study was to identify the cell type(s) responsible for the liver uptake of phosphorothioate oligodeoxynucleotides and to examine the mechanisms involved. In our study we used ISIS-3082, a phosphorothioate antisense oligodeoxynucleotide specific for murine ICAM-1. Intravenously injected [3H]ISIS-3082 (dose: 1 mg/kg) was cleared from the circulation of rats with a half-life of 23.3+/-3.8 min. At 90 min after injection (>90% of [3H]ISIS-3082 cleared), the liver contained the most radioactivity, whereas the second-highest amount was recovered in the kidneys (40.5+/- 1.4% and 17.9+/-1.3% of the dose, respectively). Of the remaining tissues, only spleen and bone marrow actively accumulated [3H]ISIS- 3082. By injecting different doses of [3H]ISIS-3082, it was found that uptake by liver, spleen, bone marrow, and kidneys is saturable, which points to a receptor-mediated process. Subcellular fractionation of the liver indicates that ISIS-3082 is internalized and delivered to the lysosomes. Liver uptake occurs mainly (for 56.1+/-3.0%) by endothelial cells, whereas parenchymal and Kupffer cells account for 39.6+/-4.5 and 4.3+/-1.7% of the total liver uptake, respectively. Preinjection of polyinosinic acid substantially reduced uptake by liver and bone marrow, whereas polyadenylic acid was ineffective, which indicates that in these tissues scavenger receptors are involved in uptake. Polyadenylic acid, but not polyinosinic acid, reduced uptake by kidneys, which suggests renal uptake by scavenger receptors different from those in the liver. We conclude that scavenger receptors on rat liver endothelial cells play a predominant role in the plasma clearance of ISIS-3082. As scavenger receptors are also expressed on human endothelial liver cells, our findings are probably highly relevant for the therapeutic application of phosphorothioate oligodeoxynucleotides in humans. If the target gene is not localized in endothelial liver cells, the therapeutic effectiveness might be improved by developing delivery strategies that redirect the oligonucleotides to the actual target cells.
Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?


This article has been cited by other articles:


Home page
 J. Exp. Biol.Home page
T. Seternes, T. C. Tonheim, M. Lovoll, J. Bogwald, and R. A. Dalmo
Specific endocytosis and degradation of naked DNA in the endocardial cells of cod (Gadus morhua L.)
J. Exp. Biol., June 15, 2007; 210(12): 2091 - 2103.
[Abstract] [Full Text] [PDF]

Home page
 Molecular Cancer TherapeuticsHome page
O. R. Mook, F. Baas, M. B. de Wissel, and K. Fluiter
Evaluation of locked nucleic acid-modified small interfering RNA in vitro and in vivo
Mol. Cancer Ther., March 1, 2007; 6(3): 833 - 843.
[Abstract] [Full Text] [PDF]

Home page
 Drug Metab. Dispos.Home page
F. M. van de Water, O. C. Boerman, A. C. Wouterse, J. G. P. Peters, F. G. M. Russel, and R. Masereeuw
INTRAVENOUSLY ADMINISTERED SHORT INTERFERING RNA ACCUMULATES IN THE KIDNEY AND SELECTIVELY SUPPRESSES GENE FUNCTION IN RENAL PROXIMAL TUBULES
Drug Metab. Dispos., August 1, 2006; 34(8): 1393 - 1397.
[Abstract] [Full Text] [PDF]

Home page
 Proc. Natl. Acad. Sci. USAHome page
H. Abe and E. T. Kool
Flow cytometric detection of specific RNAs in native human cells with quenched autoligating FRET probes
PNAS, January 10, 2006; 103(2): 263 - 268.
[Abstract] [Full Text] [PDF]

Home page
 Mol. Pharmacol.Home page
M. Bartsch, A. H. Weeke-Klimp, H. W. M. Morselt, A. Kimpfler, S. A. Asgeirsdottir, R. Schubert, D. K. F. Meijer, G. L. Scherphof, and J. A. A. M. Kamps
Optimized Targeting of Polyethylene Glycol-Stabilized Anti-Intercellular Adhesion Molecule 1 Oligonucleotide/Lipid Particles to Liver Sinusoidal Endothelial Cells
Mol. Pharmacol., March 1, 2005; 67(3): 883 - 890.
[Abstract] [Full Text] [PDF]

Home page
 Nucleic Acids ResHome page
K. Fluiter, A. L. M. A. ten Asbroek, M. B. de Wissel, M. E. Jakobs, M. Wissenbach, H. Olsson, O. Olsen, H. Oerum, and F. Baas
In vivo tumor growth inhibition and biodistribution studies of locked nucleic acid (LNA) antisense oligonucleotides
Nucleic Acids Res., February 1, 2003; 31(3): 953 - 962.
[Abstract] [Full Text] [PDF]

Home page
 J. Pharmacol. Exp. Ther.Home page
M. K. Bijsterbosch, M. Manoharan, R. Dorland, R. van Veghel, E. A. L. Biessen, and T. J. C. van Berkel
bis-Cholesteryl-Conjugated Phosphorothioate Oligodeoxynucleotides Are Highly Selectively Taken Up by the Liver
J. Pharmacol. Exp. Ther., August 1, 2002; 302(2): 619 - 626.
[Abstract] [Full Text] [PDF]

Home page
 Am. J. Physiol. Gastrointest. Liver Physiol.Home page
J. Wong, P. Kubes, Y. Zhang, Y. Li, S. J. Urbanski, C. F. Bennett, and S. S. Lee
Role of ICAM-1 in chronic hepatic allograft rejection in the rat
Am J Physiol Gastrointest Liver Physiol, July 1, 2002; 283(1): G196 - G203.
[Abstract] [Full Text] [PDF]

Home page
 Proc. Natl. Acad. Sci. USAHome page
T. Seternes, K. Sorensen, and B. Smedsrod
Scavenger endothelial cells of vertebrates: A nonperipheral leukocyte system for high-capacity elimination of waste macromolecules
PNAS, May 28, 2002; 99(11): 7594 - 7597.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Res.Home page
K. Fluiter, A. L. M. A. ten Asbroek, M. van Groenigen, M. Nooij, M. C. G. Aalders, and F. Baas
Tumor Genotype-specific Growth Inhibition in Vivo by Antisense Oligonucleotides against a Polymorphic Site of the Large Subunit of Human RNA Polymerase II
Cancer Res., April 1, 2002; 62(7): 2024 - 2028.
[Abstract] [Full Text] [PDF]

Home page
 J. Pharmacol. Exp. Ther.Home page
R. F. Minchin, D. Carpenter, and R. J. Orr
Polyinosinic Acid and Polycationic Liposomes Attenuate the Hepatic Clearance of Circulating Plasmid DNA
J. Pharmacol. Exp. Ther., March 1, 2001; 296(3): 1006 - 1012.
[Abstract] [Full Text]

Home page
 Nucleic Acids ResHome page
S. D. Patil and D. G. Rhodes
Conformation of oligodeoxynucleotides associated with anionic liposomes
Nucleic Acids Res., November 1, 2000; 28(21): 4125 - 4129.
[Abstract] [Full Text] [PDF]

Home page
 Pharmacol. Rev.Home page
L. Q. Sun, M. J. Cairns, E. G. Saravolac, A. Baker, and W. L. Gerlach
Catalytic Nucleic Acids: From Lab to Applications
Pharmacol. Rev., September 1, 2000; 52(3): 325 - 348.
[Abstract] [Full Text] [PDF]

Home page
 Nucleic Acids ResHome page
M. K. Bijsterbosch, E. T. Rump, R. L. A. D. Vrueh, R. Dorland, R. van Veghel, K. L. Tivel, E. A. L. Biessen, T. J. C. van Berkel, and M. Manoharan
Modulation of plasma protein binding and in vivo liver cell uptake of phosphorothioate oligodeoxynucleotides by cholesterol conjugation
Nucleic Acids Res., July 15, 2000; 28(14): 2717 - 2725.
[Abstract] [Full Text] [PDF]

Home page
 Nucleic Acids ResHome page
P. d. Diesbach, C. Berens, F. N'Kuli, M. Monsigny, E. Sonveaux, R. Wattiez, and P. J. Courtoy
Identification, purification and partial characterisation of an oligonucleotide receptor in membranes of HepG2 cells
Nucleic Acids Res., February 15, 2000; 28(4): 868 - 874.
[Abstract] [Full Text] [PDF]

Home page
 J. Pharmacol. Exp. Ther.Home page
S. K. Klimuk, S. C. Semple, P. N. Nahirney, M. C. Mullen, C. F. Bennett, P. Scherrer, and M. J. Hope
Enhanced Anti-Inflammatory Activity of a Liposomal Intercellular Adhesion Molecule-1 Antisense Oligodeoxynucleotide in an Acute Model of Contact Hypersensitivity
J. Pharmacol. Exp. Ther., February 1, 2000; 292(2): 480 - 488.
[Abstract] [Full Text]

Home page
 J. Pharmacol. Exp. Ther.Home page
M. Butler, R. M. Crooke, M. J. Graham, K. M. Lemonidis, M. Lougheed, S. F. Murray, D. Witchell, U. Steinbrecher, and C. F. Bennett
Phosphorothioate Oligodeoxynucleotides Distribute Similarly in Class A Scavenger Receptor Knockout and Wild-Type Mice
J. Pharmacol. Exp. Ther., February 1, 2000; 292(2): 489 - 496.
[Abstract] [Full Text]

Home page
 J. Pharmacol. Exp. Ther.Home page
M. J. Graham, S. T. Crooke, D. K. Monteith, S. R. Cooper, K. M. Lemonidis, K. K. Stecker, M. J. Martin, and R. M. Crooke
In Vivo Distribution and Metabolism of a Phosphorothioate Oligonucleotide within Rat Liver after Intravenous Administration
J. Pharmacol. Exp. Ther., July 1, 1998; 286(1): 447 - 458.
[Abstract] [Full Text]


Disclaimer:
Please note that abstracts for content published before 1996 were created through digital scanning and may therefore not exactly replicate the text of the original print issues. All efforts have been made to ensure accuracy, but the Publisher will not be held responsible for any remaining inaccuracies. If you require any further clarification, please contact our Customer Services Department.